Starovoĭt A V, Pastushenkov V L, Shitov A Iu, Miasnikov A A
Med Tr Prom Ekol. 2010(9):40-5.
The article deals with evaluation of efficiency of metabolic cytoprotector Remaxol as a medication for urgently increased stability towards acute decompression syndrome at severe degree, studied in experiments on 45 outbred male rabbits. Single intravenous injection of Remaxol relieves oxidant effects of inadequate decompression, lowers number of lethal outcomes due to acute decompression syndrome, increases survival time in the animals.
本文探讨了代谢性细胞保护剂Remaxol作为一种药物在严重程度下紧急提高对急性减压综合征稳定性的效果，该研究在45只雄性杂种兔身上进行。单次静脉注射Remaxol可减轻减压不足的氧化作用，降低急性减压综合征导致的致死率，延长动物的存活时间。
